Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study

Open access

Abstract

Background In vitro, disulfiram activated HIV transcription in a primary T-cell model of HIV latency and in a pilot clinical study increased plasma HIV RNA in individuals with adequate drug exposure. We assessed the effect of disulfiram on HIV transcription in a dose-escalation study.Methods In this prospective dose-escalation study, to optimise disulfiram exposure we included adults with HIV on suppressive antiretroviral therapy, with plasma HIV RNA of less than 50 copies per mL and a CD4 cell count greater than 350 cells per μL. Participants were allocated sequentially to one of three dosing groups (500 mg, 1000 mg, and 2000 mg) and received disulfiram daily for 3 days. Only the staff who did laboratory assays were masked to group assignment. The primary endpoint was change in cell-associated unspliced HIV RNA in CD4 cells. The primary analysis method was a negative binomial regression, with the number of copies as the outcome variable and the input total RNA or plasma volume as an exposure variable, which is equivalent to modelling copies or input. We used these models to estimate changes from before disulfiram to timepoints during and after disulfiram administration. This study is registered with ClinicalTrials.gov, number NCT01944371.Findings Of 34 participants screened for eligibility at The Alfred Hospital (Melbourne, VIC, Australia), and San Francisco General Hospital (San Francisco, CA, USA), 30 people were enrolled between Sept 24, 2013, and March 31, 2014. The estimated fold increases in cell-associated unspliced HIV RNA from baseline were 1·7 (95% CI 1·3-2·2; p<0·0001) to the timepoint during disulfiram treatment and 2·1 (1·5-2·9; p<0·0001) to the timepoint after disulfiram in the 500 mg group; 1·9 (1·6-2·4; p<0·0001) and 2·5 (1·9-3·3; p<0·0001) in the 1000 mg group; and 1·6 (1·2-2·1; p=0·0026) and 2·1 (1·5-3·1; p=0·0001) in the 2000 mg group. No deaths occurred, and no serious adverse events were noted. Disulfiram was well tolerated at all doses.Interpretation Short-term administration of disulfiram resulted in increases in cell-associated unspliced HIV RNA at all doses, consistent with activating HIV latency. Disulfiram may be suited for future studies of combination and prolonged therapy to activate latent HIV.Funding The Foundation for AIDS Research (amfAR); National Institute of Allergy and Infectious Diseases, National Institutes of Health; Australian National Health and Medical Research Council.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2352-3018(15)00226-x

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 1

  1. Williams, 1937, Effects of alcohol on workers with carbon disulfide, J Am Med Assoc, 109, 1472

Cited by

See all 250

Metadata

Authors
Elliott, J. H., McMahon, J. H., Chang, C. C., Lee, S. A., Hartogensis, W., Bumpus, N., Savic, R., Roney, J., Hoh, R., Solomon, A., Piatak, M., Gorelick, R. J., Lifson, J., Bacchetti, P., Deeks, S. G., & Lewin, S. R.
Affiliations
  • The Alfred Hospital (AU)
  • The University of Melbourne (AU)
  • University of California, San Francisco (US)
  • Leidos Biomedical Research Inc. (United States) (US)
Corresponding author
Lewin, Sharon R
Venue
The Lancet HIV
Publisher
Elsevier BV
Published
2015-12
Volume
2
Issue
12
Pages
e520-e529
ISSN
2352-3018 (ISSN-L)
OpenAlex
W2177904182
Cited by
250
References
29
Citations by year
2026: 10 · 2025: 17 · 2024: 9 · 2023: 24 · 2022: 22 · 2021: 25 · 2020: 32 · 2019: 25 · 2018: 43 · 2017: 25 · 2016: 14 · 2015: 4
FWCI
14.51
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet HIV (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion)
Funders
  • Foundation for AIDS Research (amfAR; 108465-52-RGRL)
  • Division of AIDS, National Institute of Allergy and Infectious Diseases, US National Institutes of Health (U19AI096109)
  • NIAID (K24 AI069994)
  • UCSF/Gladstone Institute of Virology & Immunology CFAR (P30 AI027763)
Topics
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
Keywords
disulfiram, HIV latency, HIV transcription, CD4+ T cells, dose escalation, antiretroviral therapy, HIV reservoir, HIV cure, negative binomial regression, adverse events, tolerability
MeSH terms
Adult, Australia, Disulfiram, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Prospective Studies, RNA, Viral, Transcription, Genetic, United States, CD4-Positive T-Lymphocytes, HIV-1, HIV Infections, Treatment Outcome, Virus Latency, CD4 Lymphocyte Count, Viral Load, Anti-Retroviral Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. https://app.cochat.ai/papers/10.1016/s2352-3018(15)00226-x
The paper
Elliott, J. H., McMahon, J. H., Chang, C. C., Lee, S. A., Hartogensis, W., Bumpus, N., Savic, R., Roney, J., Hoh, R., Solomon, A., Piatak, M., Gorelick, R. J., Lifson, J., Bacchetti, P., Deeks, S. G., & Lewin, S. R. (2015). Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. The Lancet HIV. https://doi.org/10.1016/s2352-3018(15)00226-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.